XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Show more

Location: 5217 Winnebago Lane, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, United States | Website: https://www.xbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

86.28M

52 Wk Range

$2.50 - $8.32

Previous Close

$2.96

Open

$2.95

Volume

57,784

Day Range

$2.83 - $2.98

Enterprise Value

-65.35M

Cash

155.9M

Avg Qtr Burn

-7.62M

Insider Ownership

35.07%

Institutional Own.

14.92%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Hutrukin Details
Brain disease, Ischemic stroke

Phase 2

Update

Natrunix + Methotrexate (MTX) Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

Natrunix w/ ON+5FU+LV Details
Cancer, Pancreatic cancer

Phase 1/2

Update

Phase 1

Update

514G3 Details
Bacterial infection, Methicillin-resistant staphylococcus aureus

Failed

Discontinued

Bermekimab Details
Skin disease/disorder

Failed

Discontinued

Bermekimab Details
Skin disease/disorder, Hidradenitis suppurativa

Failed

Discontinued